Inogen, Inc $INGN Shares Bought by Monaco Asset Management SAM

Monaco Asset Management SAM grew its holdings in Inogen, Inc (NASDAQ:INGN) by 6.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 177,594 shares of the medical technology company’s stock after purchasing an additional 10,000 shares during the period. Monaco Asset Management SAM’s holdings in Inogen were worth $1,248,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. CWM LLC lifted its position in Inogen by 11.0% in the second quarter. CWM LLC now owns 16,258 shares of the medical technology company’s stock valued at $114,000 after buying an additional 1,611 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in Inogen by 1.4% in the 1st quarter. Cubist Systematic Strategies LLC now owns 124,993 shares of the medical technology company’s stock valued at $891,000 after purchasing an additional 1,751 shares during the last quarter. American Century Companies Inc. lifted its stake in Inogen by 6.4% during the first quarter. American Century Companies Inc. now owns 58,380 shares of the medical technology company’s stock worth $416,000 after purchasing an additional 3,524 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Inogen by 61.6% during the first quarter. Deutsche Bank AG now owns 14,856 shares of the medical technology company’s stock worth $106,000 after buying an additional 5,664 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its stake in shares of Inogen by 44.9% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 20,078 shares of the medical technology company’s stock valued at $150,000 after buying an additional 6,220 shares in the last quarter. 89.94% of the stock is owned by institutional investors and hedge funds.

Inogen Trading Down 0.6%

NASDAQ:INGN opened at $6.99 on Friday. Inogen, Inc has a 12-month low of $5.70 and a 12-month high of $12.91. The firm has a market cap of $189.01 million, a PE ratio of -6.92 and a beta of 1.83. The stock has a fifty day moving average price of $8.34 and a 200 day moving average price of $7.35.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Wednesday, November 5th. The medical technology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. The company had revenue of $92.39 million for the quarter, compared to analyst estimates of $92.20 million. Inogen had a negative return on equity of 13.21% and a negative net margin of 7.31%. Inogen has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that Inogen, Inc will post -1.73 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $11.00.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.